Trial Profile

Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Sep 2025 According to a CARsgen media release, updated long-term follow-up results of phase I clinical trial of zevorcabtagene autoleucel has been presented as a poster at the 22nd International Myeloma Society (IMS) Annual Meeting.
17 Sep 2025 Results published in a CARsgen media release
14 Dec 2021 Results of pooled analysis from NCT03380039, NCT03716856, NCT03302403 and NCT03975907; assessing efficacy and safety of CT053 in Chinese subjects with Relapsed and Refractory Multiple Myeloma based on high-risk factors, presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com